A new study from Karolinska Institutet and the Karolinska University Hospital indicates that only a rather small proportion of individuals attending a specialized memory clinic have an Alzheimer’s disease-type biomarker profile and could be considered eligible for novel disease-modifying treatments targeting amyloid.